Kidney Cancer

Patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who receive first-line cabozatinib after checkpoint inhibitor combination therapy appear to have early responses.

Updated results from the phase 3 CheckMate 9ER trial continue to support nivolumab plus cabozantinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

When combined with nivolumab and ipilimumab, cabozantinib appears to improve outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among the poor-risk population.

The addition of everolimus to vorolanib appears to improve outcomes in metastatic renal cell carcinoma.

Experts review key clinical data and current treatment strategies for renal cell carcinoma following updates from the 2022 IKCS meeting.

Treatment with nivolumab plus ipilimumab appears to result in overall survival and progression-free survival benefit in patients with intermediate- or poor-risk sarcomatoid renal cell carcinoma.

Experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.

Before closing out their discussion on renal cell carcinoma, key opinion leaders highlight efforts to optimize the management of non–clear cell disease with immunotherapy.

Findings from the phase 3 LEAP-002 study indicate that the addition of pembrolizumab to lenvatinib did not impact quality-of-life scores among patients with hepatocellular carcinoma.

Lenvatinib yields survival benefit in hepatocellular carcinoma following progression on immunotherapy.

An expert from the University of Texas MD Anderson Cancer Center discussed kidney cancer treatment updates from a recent medical conference.

Contextualizing discussion with clinical trial data and real-world experience, expert hematologist-oncologists consider the role of adjuvant therapy in managing advanced RCC.

Shared insight from Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, on unmet needs in the setting of clear cell and non–clear cell renal cell carcinoma.

Data from a meta-analysis suggest that single-fraction stereotactic ablative body radiotherapy could result in a lower incidence of local failure than multifractionated radiation in patients with renal cell carcinoma.

Key opinion leaders reflect on novel treatment modalities still under investigation for the management of advanced renal cell carcinoma.

Expert hematologist-oncologists share comprehensive perspective on an array of first-line clinical trials in the setting of advanced renal cell carcinoma.

A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.

Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.

Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.

Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.

An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.

Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.

Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.

“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.

Before closing out their discussion on the evolving treatment landscape of advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, highlight clinical trials in the adjuvant setting.

Shared insight on the results from triplet therapy–centered clinical trials in advanced renal cell carcinoma and how these might inform treatment strategies as the paradigm continues to evolve.

Experts Matthew Campbell, MD, MS, and Brian Rini, MD, provide a brief review of recent clinical data in the setting of relapsed/refractory renal cell carcinoma.

A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice.

Closing out their discussion on adverse event management in advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, consider overlapping toxicity in TKI/IO regimens.

Expert perspectives on the most common adverse events seen while managing advanced renal cell carcinoma, followed by advice on how best to manage these and counsel patients.